University of Birmingham The Liver Toxicity Knowledge Base (LKTB) and Drug-Induced Liver Injury (DILI) classification for assessment of human liver injury

•Users may freely distribute the URL that is used to identify this publication. •Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research. •User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain.

[1]  Weida Tong,et al.  A Model to predict severity of drug‐induced liver injury in humans , 2016, Hepatology.

[2]  W. Tong,et al.  Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles. , 2016, Chemico-biological interactions.

[3]  Minjun Chen,et al.  Drug-induced liver injury: Interactions between drug properties and host factors. , 2015, Journal of hepatology.

[4]  K. Yu,et al.  High Daily Dose and Being a Substrate of Cytochrome P450 Enzymes Are Two Important Predictors of Drug-Induced Liver Injury , 2014, Drug Metabolism and Disposition.

[5]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[6]  Weida Tong,et al.  Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[7]  Emilio Benfenati,et al.  A comparative survey of chemistry-driven in silico methods to identify hazardous substances under REACH. , 2013, Regulatory toxicology and pharmacology : RTP.

[8]  Weida Tong,et al.  High lipophilicity and high daily dose of oral medications are associated with significant risk for drug‐induced liver injury , 2013, Hepatology.

[9]  H Fang,et al.  The Liver Toxicity Knowledge Base: A Systems Approach to a Complex End Point , 2013, Clinical pharmacology and therapeutics.

[10]  David M. Reif,et al.  Profiling 976 ToxCast Chemicals across 331 Enzymatic and Receptor Signaling Assays , 2013, Chemical research in toxicology.

[11]  J. Serrano,et al.  LiverTox: A website on drug‐induced liver injury , 2013, Hepatology.

[12]  Weida Tong,et al.  Translating Clinical Findings into Knowledge in Drug Safety Evaluation - Drug Induced Liver Injury Prediction System (DILIps) , 2011, PLoS Comput. Biol..

[13]  Weida Tong,et al.  FDA-approved drug labeling for the study of drug-induced liver injury. , 2011, Drug discovery today.

[14]  Cyrille Krul,et al.  Toxicology in the 21st century--working our way towards a visionary reality. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[15]  Hannu Raunio,et al.  In Silico Toxicology – Non-Testing Methods , 2011, Front. Pharmacol..

[16]  Nigel Greene,et al.  Developing structure-activity relationships for the prediction of hepatotoxicity. , 2010, Chemical research in toxicology.

[17]  William M. Lee,et al.  Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in VigiBase™ , 2010, Drug safety.

[18]  H. Yamada,et al.  The Japanese toxicogenomics project: application of toxicogenomics. , 2010, Molecular nutrition & food research.

[19]  Peter V. Henstock,et al.  Cellular imaging predictions of clinical drug-induced liver injury. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[20]  Weida Tong,et al.  Mold2, Molecular Descriptors from 2D Structures for Chemoinformatics and Toxicoinformatics , 2008, J. Chem. Inf. Model..

[21]  Wolfgang Muster,et al.  Computational toxicology in drug development. , 2008, Drug discovery today.

[22]  P. Bernardi,et al.  High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening , 2006, Archives of Toxicology.

[23]  M. Fielden,et al.  Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. , 2005, Journal of biotechnology.

[24]  J. Guo,et al.  Comparison of potentially hepatotoxic drugs among major US drug compendia. , 2005, Research in social & administrative pharmacy : RSAP.

[25]  H Hong,et al.  An in silico ensemble method for lead discovery: decision forest , 2005, SAR and QSAR in environmental research.

[26]  Neil Kaplowitz,et al.  Idiosyncratic drug hepatotoxicity , 2005, Nature Reviews Drug Discovery.

[27]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[28]  P Smith,et al.  Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.

[29]  Cheshire Sk.  A Correlation Between the In Vitro Drug Toxicity of Drugs to Cell Lines That Express Human P450s and Their Propensity to Cause Liver Injury in Humans , 2013 .

[30]  T. Brody.  Clinical trials : study design, endpoints and biomarkers, drug safety, FDA and ICH guidelines , 2012 .